Medclair (MCLR) Q1 2026 earnings summary

Executive summary

• Net sales increased to SEK 18.2 million in Q1 2026 from SEK 15.6 million year-over-year, with profit after tax at SEK 3.8 million (4.0).

• Gross margin remained above 66%, reflecting operational strength and stable profitability.

• Significant technological advancements and new product launches, including EXPO.p and the Collection Unit, are driving expansion and recurring revenue.

• Expansion into new markets and segments, including recycling and pharmaceutical production, broadens the addressable market.

Financial highlights

• Order intake was SEK 16.1 million, down from SEK 22.0 million year-over-year.

• EBITDA reached SEK 5.1 million (5.7), and earnings per share after tax were SEK 0.04 (0.05).

• Cash and cash equivalents at period end were SEK 20.4 million (3.6), with no long-term liabilities.

• Equity increased to SEK 79.2 million (53.0), supported by a SEK 21.7 million share issue.

Outlook and guidance

• Global demand is rising, driven by regulatory and sustainability trends, with strong growth potential in dental and recycling segments.

• The new technology platform is expected to accelerate expansion, increase recurring revenue, and strengthen market position.

• The total addressable market is estimated at SEK 17 billion, with ongoing efforts to strengthen direct sales in core markets.